SLC31A1 and breast cancer: In terms of breast cancer, SLC31A1 expression was markedly decreased in non-response groups compared with response groups, when patients were treated with widely used chemotherapy regimens including FEC (fluorouracil, epirubicin, cyclophosphamide) plus docetaxel (Fig. 8B), TA (taxane, anthracycline) (Fig. 8D), and FEC (fluorouracil, epirubicin, cyclophosphamide) plus paclitaxel (Fig. 8F).